Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FORTITUDE-3: AOC 1020 for FSHD
NCT07038200Phase 3Recruiting
- Sponsor
- Avidity Biosciences
- Start
- Jun 2025
- Primary completion
- May 2028
- Modality
- Antisense DNA, Antibody-Drug Conjugates (ADCs), Conjugated siRNA
- Countries
- 10
01
Overview
Phase 3, randomised, double-blind trial in facioscapulohumeral muscular dystrophy (FSHD) comparing Del-brax with Placebo (2 arms). Primary endpoint: Quantitative Muscle Testing total composite score (PPN) at 78 weeks. Started Jun 2025; status: recruiting.
02
Drugs
delpacibart braxlosiran
03
Conditions
facioscapulohumeral muscular dystrophy (FSHD)
Beyond the preview
Go deeper on NCT07038200.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07038200.